Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReproductive Health & FertilityAetna Infertility Coverage & Prior Auth Policy Upd…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0327

    Infertility

    Customize your policy alerts

    Sign up for Aetna Policy 0327 alerts

    Get alerted when Policy 0327 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Aetna's clinical policy bulletin governing diagnostic evaluation and treatment of infertility for commercial medical plans, including coverage criteria, required precertification for certain injectable medications, and definitions of infertility and eligibility. Applies to members whose plans provide infertility benefits.

    Policy Summary
    PayerAetna
    PolicyInfertility
    Policy CodePolicy 0327
    Change TypeNo material change
    Effective Date05/20/1999
    Last ReviewFeb 15, 2024
    Next Review Date07/25/2024
    Key ActionObtain precertification for listed injectable infertility medications and submit required SMN forms as specified.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    02/15/2024last review date
    05/20/1999effective date
    07/25/2024next review
    3ART trial requirement (≤37)
    6AI cycles (typical)

    Coverage Criteria and Medical Necessity

    Covered services and clinical criteria

    Covered when ALL applicable plan provisions are met and when member meets the stated clinical criteria:

    General eligibility: Member's plan must provide coverage for infertility services; coverage is subject to plan terms and state mandates

    See plan documents

    Definition of infertility: Failure to conceive after specified duration (12 months if female <35 years; 6 months if female >=35 years) OR defined cycles of timed insemination OR demonstration of reproductive tract disease making conception ineffective

    Applies regardless of partner availability

    Female diagnostic services covered: History and physical, specified laboratory testing (e.g., serum hormones including AMH, FSH/LH, prolactin, TSH; infectious disease screening), imaging and diagnostic procedures (endometrial biopsy, HSG, hysteroscopy, laparoscopy, transvaginal ultrasound) and monitoring of ovarian response

    Some tests/procedures have appendix-specified limitations

    Female non-surgical and surgical treatments: Medications (aromatase inhibitors, clomiphene, metformin, progestins, estrogens, selected corticosteroids), vaccinations, gynecologic surgeries (hysteroscopic adhesiolysis, tubal cannulation, laparoscopy, endometriosis surgery, ovarian drilling, tubal reconstruction, salpingectomy for hydrosalpinx when indicated)

    Coverage may vary by plan; injectable medications often require precertification

    Male diagnostic services covered: History and physical, semen analysis with repeat-testing rules, selected labs (hormones, genetic testing where indicated), imaging and testis/epididymal biopsy as clinically indicated

    Some specialized seminal biochemical tests are considered investigational

    Artificial insemination indications: IUI/ICI considered medically necessary for any of: mild male-factor infertility; unexplained infertility; minimal–mild endometriosis; refractory erectile dysfunction or vaginismus; HIV-positive male with sperm washing; couples undergoing menotropin stimulation; or clomiphene-stimulated AI in ovulatory WHO Group II disorders

    Definition of mild male-factor: >=2 semen analyses at least 2 weeks apart with 1+ variables below 5th percentile

    Advanced reproductive technologies (ART): IVF, FET, oocyte retrieval, sperm preparation, and related ART procedures are medically necessary when any ART criteria are met (e.g., failed trial of ovarian stimulation per age rules; tubal factor including bilateral disease; severe male-factor such that insemination unlikely to succeed; endometriosis stage III/IV; other conditions where insemination is unlikely to be effective)

    Coverage limited to plans with an ART benefit; ICSI medically necessary for specified sperm/ fertilization indications

    Medication therapy criteria: Gonadotropins (follitropins, menotropins, hCG) are medically necessary when indicated per drug-specific initial approval criteria (e.g., prior clomiphene cycles, risk factors for poor response, contraindication to clomiphene, or age >=37 where specified); continuation requires meeting initial authorization criteria

    Many plans exclude injectable infertility medications; precertification may be required

    Cryopreservation indications: Cryopreservation of gametes or embryos is medically necessary when undertaken for iatrogenic infertility risk (e.g., chemotherapy, pelvic radiotherapy, gonadectomy); routine/elective cryopreservation to circumvent aging is not covered

    Some plans exclude storage/cryopreservation fees—check benefits

    Medical necessity: Artificial insemination, ART, continuation therapy, cryopreservation

    Covered when ALL/ANY as specified below

    Artificial insemination medical necessity: Artificial insemination (ICI or IUI) is medically necessary for any of: mild male-factor infertility; unexplained infertility; minimal to mild endometriosis; medically refractory erectile dysfunction or vaginismus preventing intercourse; HIV-positive male with sperm washing; couples undergoing menotropin ovarian stimulation; or clomiphene-stimulated AI for WHO Group II ovulation disorders who ovulate with clomiphene but have not become pregnant.

    Mild male-factor defined by >=2 semen analyses at least 2 weeks apart with 1+ variables below 5th percentile

    ART medical necessity: ART procedures (including IVF with embryo transfer, FET, oocyte retrieval, sperm preparation, ICSI when indicated, GIFT/ZIFT for female factor) are medically necessary when any of: failed trial of ovarian stimulation per age-based rules (3 cycles if <=37; none required if >=38); conditions where insemination unlikely to be effective (e.g., azoospermia, severe semen deficits, bilateral tubal disease, endometriosis stage 3/4); failure to conceive after pelvic reconstruction per timeframes; ectopic pregnancy during infertility treatment; unilateral hydrosalpinx meeting timing criteria; women post-hysterectomy or with contraindication to pregnancy where gestational carrier indicated.

    ICSI indicated for azoospermia/oligospermia, severe semen deficits, fertilizing frozen oocytes, iatrogenic infertility, or prior failed/poor fertilization; ICSI not necessary if sperm normalized after varicocelectomy

    Ovarian stimulation coverage criteria

    Covered when ALL of the following are met

    Ovarian responsiveness criteria: Member demonstrates biologic capacity to respond to ovarian stimulation as evidenced by an unmedicated day-3 FSH obtained within the prior 6 months for women older than 35 years or within the prior 12 months for women age 35 or youngerDay-3 FSH timing per age

    In women >40 any single FSH >19 mIU/mL indicates ovarian insufficiency; in women <40 responsiveness shown by any unmedicated day-3 FSH <19 mIU/mL

    Evidence-based coverage statements

    Coverage stance based on cited evidence and guideline statements:

    Luteal phase support: Progesterone is the preferred agent for luteal phase support in ART; hCG is associated with increased OHSS risk and should be avoided; addition of GnRH agonist to progesterone showed benefit in some trials

    Based on Cochrane review of 69 studies (progesterone benefit; hCG increased OHSS; some benefit with progesterone + GnRH agonist)

    In‑vitro maturation (IVM): IVM and cryopreservation of immature oocytes are considered experimental and should be limited to specialized centers and research settings until RCT evidence supports routine use

    No suitable RCTs for IVM vs conventional IVF in PCOS

    Preimplantation genetic screening/diagnosis (PGS/PGD-A): PGS#2 and PGD-A have uncertain clinical utility; evidence is mixed and procedure should be considered experimental outside study conditions

    Lack of properly conducted intent-to-treat trials; professional societies caution use

    Evidence summaries (informational)

    Evidence and clinical conclusions relevant to coverage decisions:

    Eeva time‑lapse embryo assessment: Time‑lapse Eeva scoring improves embryologist specificity for selecting embryos likely to reach usable blastocyst stage in cohort studies, but current evidence is insufficient to support routine clinical use for improving embryo selection

    Prospective cohort and multicenter studies showed improved specificity and implantation associations; overall evidence deemed inadequate for routine use

    DuoStim evidence summary: DuoStim (double stimulation within one ovarian cycle) increases oocyte and euploid blastocyst yield in poor‑prognosis cohorts, with comparable competence of luteal‑phase oocytes, but lacks RCTs and long‑term safety/cost‑effectiveness data

    Observational and paired studies report higher oocyte/euploid yield; authors recommend limiting to poor prognosis/time‑critical patients pending further trials

    POLG CAG‑repeat testing: Meta-analysis found no association between POLG CAG‑repeat polymorphisms and male infertility; testing for this variant is not supported by current evidence

    Pooled case‑control studies did not demonstrate association

    Coverage and use criteria

    Coverage stance based on current evidence in included chunks

    DuoStim — conditional coverage: DuoStim may be considered only for poor‑prognosis patients and/or when time is critical, pending further randomized trials and safety data

    Authors recommend restricting use until RCTs and safety/cost data are available

    ERA — selective/research use: ERA demonstrated per‑protocol benefits in one RCT but ITT results were limited; routine use in unselected first autologous euploid FET cycles is not supported — consider ERA only in research protocols or selected populations (e.g., recurrent implantation failure) with documented counseling

    Mixed evidence from RCT and cohort studies; further trials required

    Vaginal microbiota and telomere associations: Associations exist between high‑Lactobacillus vaginal microbiota and infertility outcomes and between telomere metrics and infertility factors, but causal inference and clinical application are not established

    Further high‑quality studies required before routine clinical application

    Coverage summaries for interventions discussed

    Summary coverage stance based on cited evidence

    PICSI (hyaluronan‑selected ICSI) is not recommended for routine use to improve term live‑birth rates based on a large randomized trial showing no significant difference versus standard ICSI

    Large RCT (HABSelect) showed no term live‑birth benefit

    Intralipid and immunotherapies: Immunotherapies including intralipid infusion are investigational for improving live‑birth outcomes and should be limited to research contexts

    Systematic reviews/meta‑analyses show controversial results and insufficient evidence for routine use

    Platelet‑rich plasma (PRP): PRP shows inconsistent evidence for thin endometrium and recurrent implantation failure; further large RCTs are required before routine adoption

    Systematic reviews indicate increased implantation/clinical pregnancy in some small studies but require confirmation

    Intrauterine hCG may improve outcomes for cleavage‑stage embryo transfers at doses >=500 IU, but evidence is heterogeneous and stage/dose dependent

    Evidence summaries and clinical considerations

    Summaries of evidence and clinical considerations for interventions

    Stem cell therapy for ovarian disorders: Systematic reviews suggest potential for ovarian tissue rejuvenation in POI models but evidence is preliminary and largely preclinical or early‑phase clinical; not routine care

    UpToDate does not list stem cell therapy as a treatment option

    Uterine transplantation (UTx) for AUFI: UTx can restore fertility in AUFI with reported live births, but is experimental with significant risks (graft failure, post‑op complications, hysterectomy in some recipients, high preterm birth rates); multidisciplinary evaluation and informed consent are essential

    Evidence is interim; centers should follow strict protocols

    Vaginal sildenafil for thin endometrium: Small RCTs and pilot studies show mixed results; insufficient evidence to support routine use

    Findings inconsistent; not standard therapy per UpToDate

    Medically necessary laboratory and medication management

    Laboratory services and medication vial management per cycle considered medically necessary when consistent with infertility treatment monitoring and FDA‑recommended dosing.

    Laboratory monitoring per cycle: Transvaginal ultrasound and serial serum measurements (estradiol, FSH, LH, progesterone, quantitative hCG) at frequencies specified in the laboratory services per‑cycle table are medically necessary for cycle monitoringsee appendix table

    More than 2 progesterone measurements may be necessary for irregular cycles

    Gonadotropin vial limits and dosing: Gonadotropin and menotropin vial/cartridge limits per 28 days and FDA‑recommended dosing (product‑specific maxima and starting doses) must be followed; standard limits and maximum daily doses are provided in the appendixproduct‑specific maxima (e.g., follitropin alfa max daily 300–450 IU depending on indication; follitropin beta max daily up to 500 IU for ART)

    Dosing individualized based on prior response; refill rules per cycle sheets

    Treatment selection and sequencing

    Treatment sequencing and choice considerations

    Initial approach for most couples: Begin with clomiphene citrate (CC)/IUI which yields pregnancy in approximately 25% of couples and has low multiple‑birth risk and low cost; accelerated IVF approaches may shorten time to pregnancy for appropriate patientsage‑related considerations apply

    Consider patient age and preferences when sequencing treatments

    When to consider gonadotropins or IVF: After failure of CC (e.g., after 6 ovulatory CC cycles), clinicians may switch to gonadotropins with or without IUI or proceed to IVF; gonadotropins increase live‑birth but at higher cost and resource useafter 6 ovulatory CC cycles

    Gonadotrophins showed higher live‑birth (52% vs 41%) with higher ICER

    Avoid COH‑IUI in patients with poor Day‑3 labs: Women with Day‑3 FSH 10–15 mIU/mL and estradiol >=40 pg/mL are unlikely to achieve live‑birth with COH‑IUI; consider proceeding directly to IVF

    Definition-based criteria

    Covered definitions when used to evaluate infertility conditions and ART outcomes:

    Embryo quality: An embryo of reasonable quality (grade B or equivalent) is defined as having less than 50% fragmentation<50% fragmentation

    Used to qualify embryos for transfer or cryopreservation

    Fertilization rate: IVF cycles with less than 50% fertilization are considered to have poor fertilization<50% fertilization

    May guide indications for techniques like ICSI

    Ovarian reserve response: Normal ovarian reserve response after gonadotropin stimulation: 3 or more follicles develop and peak estrogen >500 mIU/ml; diminished reserve indicated by peak estrogen <500 mIU/ml or fewer than 3 mature follicles>=3 follicles; peak estrogen >=500 mIU/ml

    Most Aetna plans exclude coverage for infertility services following prior sterilization procedures (including tubal sterilization and vasectomy) and for persons who have undergone hysterectomy; such services are considered elective and not treatment of disease. Providers should check the member’s benefit plan description for plan-specific exclusions and limitations. (See examples and plan-check note in policy.)

    Surgical reversal of sterilization (e.g., tubal anastomosis or vasovasostomy) and related services are generally not covered under plans that specifically exclude services after voluntary sterilization; verify member benefits before authorization.

    IVF cycles performed solely for the purpose of embryo banking (when embryos are created but none are used in the contemporaneous cycle) and routine gamete cryopreservation to delay reproductive aging in healthy persons are considered elective and are not covered. Cryopreservation and long‑term storage charges for donor or elective gamete/embryo services may be excluded by some plans; verify plan provisions.

    Cryopreservation of mature gametes or embryos is considered medically necessary only for persons facing iatrogenic infertility (for example, due to chemotherapy, pelvic radiotherapy, or planned gonad removal). Cryopreservation of immature gametes (and IVM of immature oocytes) is considered experimental/investigational and is not routinely covered.

    The policy lists specific CPT/HCPCS and related codes that are not covered for the indications described in this Clinical Policy Bulletin (examples include codes for certain genetic evaluations, Endometrial Receptivity Analysis/ERA, cryopreservation of immature oocytes, and selected HCPCS listed as not covered). Providers should consult the CPB code lists when determining coverage for services.

    Examples of HCPCS/CPT entries cited as not covered for CPB indications include hyaluronan sperm binding testing (0087T), platelet-rich plasma injections (0232T), cryopreservation of immature oocytes (0357T), and assorted HCPCS items enumerated in the policy appendix; certain ICD-10 codes (e.g., N92.4, N95.0–N95.9) are also identified as not covered for listed indications.

    For women under age 40, ovarian responsiveness for use of their own oocytes is demonstrated by an unmedicated day‑3 serum FSH of < 19 mIU/mL on the most recent test. For women age 40 and older, any single unmedicated day‑3 FSH > 19 mIU/mL indicates ovarian insufficiency and precludes use of own oocytes unless a subsequent test documents FSH < 19 mIU/mL as specified by plan rules.

    When premature ovarian failure (primary ovarian insufficiency) is present, oocyte donation is an accepted effective option and ART using donor oocytes is considered medically necessary up to age 45 per the policy; check plan details for any age‑based limits.

    The policy identifies specific ICD‑10 diagnosis codes that are not covered for the indications listed in this CPB; examples called out include codes for menopausal and perimenopausal disorders and selected menstrual disorder codes (for example, N92.4 and N95.0–N95.9). Providers should use the CPB code lists and verify applicable plan coverage before submitting claims.

    Additional ICD‑10 entries referenced in the appendix (e.g., Z31.0 for reversal of previous sterilization, Z78.0 asymptomatic menopausal state, and Z90.* acquired absence codes) are shown for guidance on applicable and excluded diagnoses; applicability depends on the plan.

    The policy characterizes several procedures and techniques as experimental or investigational and not standard care outside research settings. These include updated preimplantation genetic screening (PGS#2/PGT‑A) where intent‑to‑treat RCT evidence is lacking, in‑vitro maturation (IVM) and cryopreservation of immature oocytes, and other emerging genetic or laboratory methods without validated clinical utility.

    Procedures considered experimental should generally be limited to specialized centers or study protocols and typically require case review or prior authorization when proposed outside research.

    Eeva (Early Embryo Viability Assessment) time‑lapse embryo scoring has shown improved specificity for predicting embryos that reach blastocyst stage in some cohort studies, but the CPB concludes that current evidence is insufficient to support routine clinical use of the Eeva test for embryo selection.

    Endometrial Receptivity Analysis (ERA) is an add‑on test that uses endometrial biopsy RNA profiles to classify the endometrium as receptive or non‑receptive and to guide personalized embryo transfer timing. Evidence is mixed: one RCT reported per‑protocol benefits but ITT analyses and cohort studies have not consistently shown improved live‑birth rates.

    Given current uncertainty, routine, widespread use of ERA as an add‑on is discouraged; ERA should be offered primarily under research protocols or selectively for patients with specific indications (for example, documented prior failed embryo transfer) with counseling and prior authorization as appropriate.

    Immunotherapies (including intralipid infusion) and stem cell–based therapies for infertility are considered experimental or investigational. Systematic reviews and meta‑analyses report controversial and inconsistent results; current evidence does not support routine clinical use outside research settings.

    Stem cell approaches for ovarian rejuvenation and related interventions remain preliminary (mostly preclinical or early‑phase clinical data); UpToDate and guideline sources do not list stem cell therapy as an established treatment for female infertility.

    Uterine transplantation (UTx) for absolute uterine factor infertility is described as an experimental, complex surgical intervention. Although UTx can restore uterine function in some recipients, evidence remains preliminary and optimal donor/recipient selection criteria are not yet established.

    UTx carries substantial perioperative morbidity and obstetric risks; prior authorization, rigorous multidisciplinary candidate evaluation, and center‑level expertise are recommended when considering this therapy.

    Some plans expressly exclude infertility services for ovarian failure or for services related to voluntary sterilization; providers must verify member benefit plan descriptions to confirm coverage eligibility prior to initiating services.

    The CPB is a partial description of benefits and does not itself determine coverage—plan documents govern specific exclusions and limits.

    Intracytoplasmic sperm injection (ICSI) is medically necessary for clear indications such as azoospermia, severe oligoasthenoteratozoospermia, fertilization failure with prior IVF cycles, or to fertilize cryopreserved oocytes. However, ICSI is considered not medically necessary when previous severe male‑factor infertility has been corrected (for example, successful varicocelectomy resulting in normalization of sperm quality/quantity).

    When sperm parameters normalize after corrective surgery (documented on repeat semen analyses performed at least two weeks apart), routine use of ICSI is not supported.

    The references section of the Clinical Policy Bulletin provides bibliographic citations used to support policy statements. This portion is references‑only and does not itself state coverage exclusions or policy criteria.

    This Clinical Policy Bulletin provides a summary of Aetna’s coverage approach for infertility services but is not a contract and does not replace member benefit plan documents. Coverage decisions depend on the member’s specific contract terms, state mandates, and plan exclusions; providers should verify benefits prior to treatment.

    Diagnostic procedures cited as examples include saline infusion sonohysterography/salino‑hysterosalpingography (e.g., Femvue) for tubal screening and selected seminal biochemical tests (such as seminal alpha‑glucosidase) used in specialized evaluations. The policy lists these procedures among many diagnostic options but also notes some are considered investigational for routine screening.

    Semen biochemical assays and specialized seminal function tests are generally considered experimental/investigational when used for routine infertility evaluation; refer to the CPB lists for specific items and coverage stance.

    The CPB enumerates a long list of procedures and laboratory tests that are considered experimental, investigational, or not medically necessary for routine infertility management. Examples include many sperm function tests (acrosome reaction, hemizona, hyaluronan binding, ROS, DNA fragmentation assays), endometrial receptivity testing (ERA/EFT), PGT‑A/PGS for routine IVF optimization, intralipid infusion, intrauterine platelet‑rich plasma infusion, DuoStim outside select poor‑responder contexts, and stem cell therapies.

    Providers should consult the detailed policy lists when planning diagnostic or adjunctive procedures; many of these services are not supported by high‑quality evidence for routine use and may be denied if billed without documented experimental/research context.

    The policy appendix provides explicit lists of HCPCS codes and CPT codes that are not covered for CPB‑specified indications (examples include certain HCPCS listed under 'not covered' such as topical hyperbaric oxygen chamber A4575 and specific immune globulin J‑codes).

    Providers should use the CPB’s coding tables to confirm whether a given CPT/HCPCS code is listed as not covered for the indicated infertility purpose prior to claim submission or authorization requests.

    Routine screening with anti‑mullerian hormone (AMH) to detect diminished ovarian reserve in low‑risk populations is not recommended. While AMH correlates with ovarian function and is useful in high‑risk women or for individualized controlled ovarian stimulation, evidence is insufficient to support AMH as a population screening tool.

    Use AMH selectively to inform treatment planning (for example, to individualize stimulation dosing) rather than as routine screening in asymptomatic, low‑risk persons.

    The routine use of adjuvant growth hormone (GH) in IVF protocols is not established. Meta‑analysis found no overall benefit in general IVF populations, although limited data suggest potential benefit in certain poor‑responder subgroups; further research is needed before routine adoption.

    Testing for Th1/Th2 ratios and intracellular cytokine assays is not supported as medically necessary for routine infertility evaluation due to lack of evidence demonstrating clinical utility. Major clinical reviews and UpToDate do not endorse these assays for management decisions.

    POLG CAG‑repeat testing is not supported as a diagnostic marker for male infertility. A pooled meta‑analysis found no association between POLG CAG‑repeat polymorphisms and male infertility and therefore routine testing for this variant is not recommended.

    ERA is not supported for routine use in unselected patients undergoing a first autologous single euploid programmed frozen embryo transfer (FET). Cohort and controlled studies, including a prospective cohort and retrospective analyses, did not demonstrate consistent improvement in live‑birth rates in unselected first‑time euploid FET cycles.

    ERA may be considered selectively (for example, in patients with documented prior implantation failures) and preferably under research protocols until stronger evidence supports broader clinical use.

    Physiologic sperm selection (PICSI) did not significantly improve full‑term live‑birth rates compared with standard ICSI in a large randomized trial and therefore is not recommended for routine use.

    Empiric intralipid infusion and other immunotherapies lack consistent high‑quality evidence of benefit and should be considered investigational outside research settings.

    Vaginal sildenafil for improving endometrial thickness or fertility outcomes is not an established therapy. UpToDate and guideline sources do not list sildenafil as a standard treatment option for female infertility, and available trials provide mixed or insufficient evidence.

    Controlled ovarian hyperstimulation with IUI (COH‑IUI) is unlikely to be beneficial for women whose Day‑3 testing shows FSH in the 10–15 mIU/mL range together with estradiol ≥ 40 pg/mL. In the referenced analyses this hormonal profile predicted no live births with COH‑IUI (100% specificity/PPV); consider proceeding directly to IVF for such patients.

    When Day‑3 FSH is 10–15 mIU/mL and E2 ≥ 40 pg/mL, counseling and treatment planning should reflect the low likelihood of COH‑IUI success.

    When a man previously met criteria for severe male‑factor infertility but subsequently normalizes sperm parameters after successful varicocelectomy (documented on repeat semen analyses), ICSI is considered not medically necessary; documentation of post‑operative normalization should be provided.

    Providers should document semen parameters on at least two occasions as specified and review prior surgical corrections before proceeding with ICSI, since coverage may be denied when semen quality has normalized after corrective treatment.

    This section of the Clinical Policy Bulletin contains the bibliographic references that support the policy text. Reference listings do not themselves confer coverage; they are provided for clinical and evidentiary context.

    Applicable Codes and Key Clinical Thresholds

    Applicable CPT / HCPCS codes listedmixed
    0167UGonadotropin, chorionic (hCG), immunoassay with direct optical observation, blood.
    0353UInfectious agent detection by nucleic acid (DNA), Chlamydia trachomatis and Neisseria gonorrhoeae, multiplex amplified probe technique, urine, vaginal, pharyngeal, or rectal, each pathogen reported as detected or not detected.
    49203Excision or destruction, open, intra-abdominal tumors, cysts or endometriomas, 1 or more peritoneal, mesenteric, or retroperitoneal primary or secondary tumors; largest tumor 5 cm diameter or less.
    49204Largest tumor 5.1 - 10.0 cm diameter.
    49205Largest tumor greater than 10.0 cm diameter.
    49320Laparoscopy, abdomen, peritoneum, and omentum, diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure).
    49321Laparoscopy, surgical; with biopsy (single or multiple).
    49322With aspiration of cavity or cyst (eg, ovarian cyst) (single or multiple).
    52402Cystourethroscopy with transurethral resection or incision of ejaculatory ducts.
    54500Biopsy of testis, needle (separate procedure).
    1–10 of 124
    1/13
    Covered CPT Codes (procedures)CPTCovered
    58660Laparoscopy, surgical; with lysis of adhesions (salpingolysis, ovariolysis) (separate procedure)
    58661With removal of adnexal structures (partial or total oophorectomy and/or salpingectomy)
    58662With fulguration or excision of lesions of the ovary, pelvic viscera, or peritoneal surface by any method
    58672With fimbrioplasty
    58673With salpingostomy (salpingoneostomy)
    58700Salpingectomy, complete or partial, unilateral or bilateral (separate procedure)
    58970Follicle puncture for oocyte retrieval, any method
    58974Embryo transfer, intrauterine
    58976Gamete, zygote, or embryo intrafallopian transfer, any method
    Imaging and radiology CPT CodesCPTCovered
    70480Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material
    70540Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s)
    74740Hysterosalpingography, radiological supervision and interpretation
    76830Ultrasound, transvaginal
    76831Saline infusion sonohysterography (SIS), including color flow Doppler, when performed
    76948Ultrasonic guidance for aspiration of ova, imaging supervision and interpretation
    Laboratory and andrology CPT CodesCPTCovered
    82166Anti-mullerian hormone (AMH)
    82670Estradiol
    84144Progesterone
    84146Prolactin
    84443Thyroid stimulating hormone (TSH)
    89300Semen analysis; presence and/or motility of sperm including Huhner test (post coital)
    89310Motility and count (not including Huhner test)
    89337Cryopreservation, mature oocyte(s)
    Specialty and case-rate CPT/HCPCS/T codesmixedCovered
    0087TSperm evaluation, Hyaluronan sperm binding test
    0232TInjection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed
    0357TCryopreservation; immature oocyte(s)
    0664TDonor hysterectomy (including cold preservation); open, from cadaver donor
    S4011In vitro fertilization; including but not limited to identification and incubation of mature oocytes, fertilization with sperm, incubation of embryo(s), and subsequent visualization for determination of development
    S4016Frozen in vitro fertilization cycle, case rate
    S4035Stimulated intrauterine insemination (IUI), case rate
    S4040Monitoring and storage of cryopreserved embryos, per 30 days
    HCPCS / J-codes / medication administration codesHCPCSCovered
    A9574Air polymer-type a intrauterine foam, 0.1 ml
    G0010Administration of hepatitis B vaccine
    J2675Injection, progesterone, per 50 mg
    J9218Leuprolide acetate, per 1 mg
    S0126Injection, follitropin alfa, 75 IU
    S0187Tamoxifen citrate, oral, 10 mg
    Other HCPCS/related codesHCPCS
    G0310Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service, 5 to 15 mins time
    S4027Storage of previously frozen embryos
    S4042Management of ovulation induction (interpretation of diagnostic tests and studies, non-face-to-face medical management of the patient), per cycle
    S8930Electrical stimulation of auricular acupuncture points; each 15 minutes
    ICD-10 covered diagnoses (examples listed)ICD-10Covered
    B20Human immunodeficiency virus [HIV] disease [HIV positive male undergoing sperm washing]
    E28.2Polycystic ovarian syndrome
    E28.39Other primary ovarian failure [poor ovarian reserve, spontaneous primary ovarian insufficiency]
    N97.0 - N97.9Female infertility
    Z31.41Encounter for fertility testing
    Z52.810 - Z52.819Egg (Oocyte) donor
    HCPCS codes listed as not covered for CPB indications (examples)HCPCSNot Covered
    S8930Electrical stimulation of auricular acupuncture points; each 15 minutes
    A4575Topical hyperbaric oxygen chamber, disposable
    J1561Injection, immune globulin, (Gamunex-C/Gammaked), nonlyophilized (e.g. liquid), 500 mg
    Applicable ICD-10 codesICD-10
    R93.811 - R93.9Abnormal findings on diagnostic imaging of other specified body structures [follow-up on hysterosalpingography abnormalities]
    T50.905+Adverse effect of unspecified drugs, medicaments and biological substances
    T66.xxx+Radiation sickness, unspecified, initial encounter
    Z11.3Encounter for screening for infections with a predominantly sexual mode of transmission [Chlamydia trachomatis screening]
    Z14.01 - Z14.02Hemophilia A carrier
    Z14.1Cystic fibrosis carrier
    Z14.8Genetic carrier of other disease [high-risk of transmitting a genetic disorder from the female partner to the offspring]
    Z20.828Contact with and (suspected) exposure to other viral communicable diseases [partners of persons infected with hepatitis B]
    Z21Asymptomatic human immunodeficiency virus [HIV] infection status
    Z23Encounter for immunization [rubella] [women susceptible to rubella]
    1–10 of 17
    1/2
    Additional ICD-10 codesICD-10
    Z31.0Encounter for reversal of previous sterilization
    Z78.0Asymptomatic menopausal state
    Z79.890Hormone replacement therapy
    Z90.79Acquired absence of other genital organ(s)
    Z98.51 - Z98.52Sterilization status
    Laboratory and medication items (no explicit billing codes provided in this excerpt)mixed
    No codes listed
    No codes listedmixed
    No codes listed
    Day 3 FSH threshold
    Day-3 FSH threshold (women <40)Unmedicated Day‑3 FSH < 19 mIU/mL in the most recent test
    Women 40 and older — useown‑egg ruleUnmedicated Day‑3 FSH must be < 19 mIU/mL in all prior tests to use own eggs
    Timing windows for Day‑3 FSHObtain unmedicated Day‑3 FSH within prior 6 months if >35 years or within prior 12 months if ≤35 years
    Ovarian stimulation trial requirement

    Precertification, Prior Authorization, and Documentation Requirements

    Prior Authorization

    Precertification Required

    Precertification is required for listed infertility injectable medications (eg, Cetrotide, ganirelix acetate, Follistim AQ, Gonal‑F, Menopur, Novarel, Pregnyl, Ovidrel, and chorionic gonadotropin). Contact Aetna Precertification at (866) 782-2779 or fax (860) 754-2515. Statement of Medical Necessity (SMN) forms are available on the Aetna Specialty Pharmacy Precertification forms page and may be required for review. Failure to obtain required precertification may result in claim denial.

    • Precertification contact: (866) 782-2779; fax: (860) 754-2515
    • SMN forms: Aetna Specialty Pharmacy Precertification forms
    Prior Authorization

    Prior Authorization May Be Required for IVF/Case‑Rate Services

    Prior authorization (medical authorization) may be required for IVF and related case‑rate services and certain ART cycle codes; selection of case‑rate or cycle codes and authorization should be confirmed during benefit verification. For some plans ART/IVF is limited to persons meeting specific infertility or ART benefit criteria — check member’s benefit plan for ART coverage limits.

    Background and Evidence Context

    BACKGROUND: Infertility is defined by ASRM as a disease characterized by the failure to achieve a successful pregnancy after 12 months or more of unprotected intercourse (for persons under age 35) or after 6 months when the female attempting conception is age 35 or older. Infertility may also be established by documented cycles of timed insemination or by demonstration of reproductive tract disease that prevents effective timed conception.

    Aetna’s coverage of diagnostic and treatment services is contingent on the member’s plan providing infertility benefits and on meeting the clinical criteria and documentation requirements outlined in the policy; plan documents and state mandates may modify definitions and coverage specifics.

    Definitions and Clinical Terms

    Infertility definition
    Infertility — duration-based definitionFailure to conceive after 12 months of frequent unprotected intercourse when female <35 years, or after 6 months when female ≥35 years
    Alternate diagnostic criteriaInfertility may also be established by specified numbers of timed insemination cycles (6 cycles if <35; 3 cycles if ≥35) or by demonstration of reproductive tract disease rendering timed contact ineffective
    ApplicabilityDefinition applies regardless of sexual orientation or presence of a reproductive partner; check plan/state mandates for variations
    Ovarian reserve / menopause rules
    Ovarian reserve / menopause rules — Day‑3 FSHWomen <40: Day‑3 unmedicated FSH must be < 19 mIU/mL in most recent test to use own eggs; Women ≥40: Day‑3 FSH must be < 19 mIU/mL in all prior tests to use own eggs
    Menopause exclusion

    Policy Dates and Revision Notes

    05/20/1999effective_date

    Policy originally became effective.

    02/15/2024last_reviewLatest

    Policy most recently reviewed.

    07/25/2024next_review_scheduled

    Next scheduled policy review date.

    Policy Summary
    PayerAetna
    PolicyInfertility
    Policy CodePolicy 0327
    Change TypeNo material change
    Effective Date05/20/1999
    Last ReviewFeb 15, 2024
    Next Review Date07/25/2024
    Key ActionObtain precertification for listed injectable infertility medications and submit required SMN forms as specified.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityApplicable Codes and Key Clinical ThresholdsPrecertification, Prior Authorization, and Documentation RequirementsBackground and Evidence ContextDefinitions and Clinical TermsPolicy Dates and Revision Notes
    Continuation of follitropins therapy is medically necessary for members requesting reauthorization who meet all initial authorization criteria.

    Follistim AQ requires prior trial of Gonal-F unless contraindicated/intolerant

    Cryopreservation of gametes or embryos is medically necessary for persons facing iatrogenic infertility due to chemotherapy, pelvic radiotherapy, other gonadotoxic therapies, or gonad removal for treatment of disease. Routine or elective cryopreservation to circumvent reproductive aging and other non-medical indications are not covered.

    Short-term cryopreservation necessary for contemporaneous use allowed per policy; check plan for storage fee coverage

    hCG for recurrent miscarriage: Evidence for hCG supplementation to prevent recurrent miscarriage is equivocal; benefit lost after removal of lower-quality trials

    Cochrane review of 5 studies (596 women) — conclusions equivocal

    Immunologic tests and therapies: Routine use of immunologic assays (e.g., Th1/Th2 ratio) and empiric immunotherapies (e.g., intralipid) is not supported; use should be within research protocols

    Systematic reviews show controversial or insufficient evidence

    CFTR testing in CBAVD: High CFTR mutation frequency in men with congenital absence of the vas deferens supports testing of the affected man and his partner and counseling about reproductive risk

    European guidelines and evidence support CFTR testing and counseling

    IC‑hCG dose >= 500 IU

    Meta‑analysis identified dose and embryo stage as important modifiers of effect

    Stem cell therapies: Stem cell–based ovarian rejuvenation is investigational; preliminary animal and small human studies suggest potential but insufficient evidence for clinical use

    UpToDate does not list stem cell therapy as a therapeutic option; further trials needed

    Uterine transplantation (UTx): UTx can restore fertility in absolute uterine factor infertility but is experimental with significant peri‑operative morbidity, notable complication and preterm birth rates; use reserved for specialized programs with multidisciplinary evaluation

    Reported series: graft function restored in many recipients but notable hysterectomy and complication rates

    Vasodilators in assisted reproduction: Cochrane review found low‑to‑moderate quality evidence with uncertain impact on live‑birth; not routinely recommended pending further large RCTs

    Evidence limited by imprecision and risk of bias

    COH‑IUI futility criteria: Women with Day‑3 FSH 10–15 mIU/mL and estradiol >=40 pg/mL were unlikely to achieve live‑birth with COH‑IUI; consider proceeding to IVF for these patientsFSH 10–15 mIU/mL AND E2 >=40 pg/mL

    Analysis reported 100% specificity/PPV for no live‑birth with COH‑IUI in referenced studies

    FSH 10–15 mIU/mL AND E2 >=40 pg/mL

    Referenced analysis reported 100% specificity/PPV for no live‑birth with COH‑IUI

    Informs prognosis and treatment planning

    Severe semen quantity: Severe deficit: unwashed total motile sperm (TMS) <10 million per ejaculate or washed TMS <3 million on two occasions at least 2 weeks apart<10 million unwashed; <3 million washed

    Meets criterion for ART interventions such as ICSI or donor sperm

    Severe semen quality deficit defined as Kruger strict morphology <4% normal forms<4%

    May indicate need for ICSI or donor sperm depending on clinical context

    WHO semen reference values: Semen analyses should be reported using WHO reference values (pH >=7.2; sperm concentration >=15 million/ml; morphology >=4% normal forms; volume >=1.5 ml; total motility >=40% or progressive >=32%; total sperm number >=39 million; vitality >=58%)see WHO values

    Use for routine reporting and interpretation

    Endometriosis staging: Endometriosis staged I–IV per ASRM definitions (I minimal; II mild; III moderate; IV severe) describing lesion depth, presence of endometriomas and adhesionsstages I–IV

    Staging informs treatment selection (e.g., ART for stage III–IV)

    Ovarian stimulation trial requirement (≤37 years)Requirement: completion of 3 cycles of ovarian stimulation (with or without IUI) before ART is considered
    Ovarian stimulation trial requirement (≥38 years)No trial of ovarian stimulation required prior to ART
    ApplicabilityRequirement applies when plan limits ART to persons who are infertile and meet age-based criteria; check plan documents
    Artificial insemination cycle limit (plan-dependent)
    Typical lifetime limitArtificial insemination cycles typically limited to 6 cycles per lifetime under plans that cover AI
    Plan variationSome Aetna plans may exclude AI entirely or apply different limits — verify benefit plan descriptions
    ScopeLimit applies to covered AI services (IUI/ICI) when plan provides AI benefit
    Embryo culture duration
    Extended embryo culture durationExtended culture of oocyte(s)/embryo(s) for 4–7 days (CPT 89272)
    CPT mappingCPT code 89272 corresponds to extended culture (4–7 days)
    Use caseApplies to blastocyst-stage culture when clinically indicated
    Day 3 FSH thresholds and timing windows for ovarian responsiveness
    Demonstrating ovarian responsivenessUnmedicated Day‑3 FSH obtained within prior 6 months if >35 years or within prior 12 months if ≤35 years
    Responsiveness threshold (women <40)Any unmedicated Day‑3 FSH < 19 mIU/mL indicates capacity to respond to stimulation in women <40
    Insufficiency threshold (women >40)Any single Day‑3 FSH > 19 mIU/mL in women >40 indicates ovarian insufficiency
    IL-17 plasma level associated with negative fertility impact
    IL‑17 plasma level threshold> 3.42 pg/ml associated with negative impact on fertility
    Study contextFinding reported from case‑control study comparing infertile versus fertile women with cytokine panels measured on day 21
    InterpretationElevated IL‑17 (>3.42 pg/ml) correlated with infertility but clinical utility not established for routine testing
    Functional ovarian cyst size used in included studies
    Functional ovarian cyst size used in studies> 20 mm (simple, functional cyst) used as definition in included trials
    Study implicationCysts >20 mm were the threshold used to evaluate cyst aspiration versus conservative management prior to COH
    Evidence conclusionNo conclusive benefit of cyst aspiration vs conservative management on clinical pregnancy in included trials
    IL-17 plasma level
    IL‑17 plasma level (duplicate)> 3.42 pg/ml associated with negative impact on fertility
    Source studyCase‑control study measuring multiple cytokines on day 21; IL‑17 elevated in infertile group
    Clinical noteReported association does not establish routine diagnostic use; further research needed
    Basal Day-3 testing thresholds predicting COH-IUI futility
    Basal Day‑3 thresholds predicting COH‑IUI futilityFSH 10–15 mIU/ml together with E2 ≥ 40 pg/ml predicted no live‑birth with COH‑IUI (100% specificity/PPV in analysis)
    Clinical implicationPatients meeting these basal hormone criteria are unlikely to benefit from COH‑IUI; consider proceeding to IVF
    Evidence sourceSecondary analysis of FASTT and FORT‑T RCTs (n=603; 2,717 cycles) reporting group 2B outcomes
    Day-3 hormone thresholds predicting COH-IUI futility (FSH 10-15 mIU/ml AND E2 >= 40 pg/ml)
    Specific Day‑3 hormone futility thresholdFSH 10–15 mIU/ml AND estradiol (E2) ≥ 40 pg/ml predict no live‑birth with COH‑IUI
    Evidence metricIn referenced analysis, specificity and PPV for no live‑birth with COH‑IUI were 100% for this profile
    Recommended actionAvoid COH‑IUI in patients with this hormonal profile; consider IVF
    Embryo/fertilization quality thresholds
    Embryo fragmentation thresholdAn embryo with < 50% fragmentation is considered reasonable quality (grade B equivalent)
    Fertilization rate thresholdIVF cycles with fertilization rate < 50% are considered poor
    Clinical useThese thresholds inform decisions about cycle outcome classification and potential next‑step interventions
    Follicle count after stimulation
    Follicle count after gonadotropin stimulation>= 3 follicles indicates normal ovarian reserve/adequate response to stimulation
    Associated estrogen thresholdNormal response also defined by peak estrogen > 500 mIU/ml after hyperstimulation
    Diminished responsePeak estrogen < 500 mIU/ml or fewer than 3 mature follicles indicates diminished ovarian reserve
    Peak estrogen level threshold for reserve
    Peak estrogen level threshold>= 500 mIU/ml after gonadotropin stimulation indicates normal ovarian reserve
    Below thresholdPeak estrogen < 500 mIU/ml indicates diminished ovarian reserve
    ContextUsed together with follicle count (>=3) to define normal ovarian reserve response
    IVF fertilization rate
    IVF fertilization rate — poor cutoffFertilization rate < 50% in an IVF cycle is considered poor
    ImplicationPoor fertilization rates may prompt consideration of ICSI or review of sperm factors and laboratory technique
    Definition sourceAppendix definitions in policy document
    Severe total motile sperm (unwashed) threshold
    Severe total motile sperm (unwashed)< 10 million total motile sperm (TMS) per ejaculate (unwashed) constitutes severe quantity deficit
    Measurement requirementDeficit should be documented on two separate occasions at least 2 weeks apart
    Clinical consequenceSevere semen quantity may indicate need for ART/ICSI or surgical sperm retrieval as indicated
    Severe total motile sperm (washed) threshold
    Severe total motile sperm (washed)< 3 million total motile sperm (TMS) on washed specimen constitutes severe deficit
    DocumentationRequire two separate abnormal results at least 2 weeks apart to define severe deficit
    Clinical implicationSevere washed TMS supports consideration of ART such as ICSI or use of donor sperm depending on context
    Kruger strict morphology threshold (<4% normal forms)
    Kruger strict morphology threshold< 4% normal forms by Kruger strict criteria indicates severe morphology deficit
    AssessmentKruger strict morphology used to define severe semen quality deficits in policy
    Clinical relevanceSevere morphology may prompt ICSI or further male fertility evaluation
    • IVF/case‑rate HCPCS examples: S4011, S4013–S4018, S4020–S4023, S4025–S4030, S4035, S4037, S4027, S4040, S4042
    • Verify ART benefit and obtain medical authorization prior to ordering/administration
    Denial Risk

    Prior Authorization for Experimental or Uncertain Procedures

    Prior authorization is recommended for procedures considered investigational, experimental, or of uncertain clinical benefit (eg, in‑vitro maturation [IVM], many add‑on immunotherapies, certain forms of expanded PGD/PGS, some novel laboratory or surgical procedures). Experimental status may lead to denial; these services should generally be performed only in research settings or specialized centers and require prior review.

    • IVM and cryopreservation of immature oocytes: considered experimental; restrict to specialized centers
    • Add‑on procedures lacking high‑quality evidence (eg, many immunotherapies, unproven PGS/PGD approaches): prior review recommended
    Prior Authorization

    Prior Authorization Suggested for DuoStim and ERA

    DuoStim (double stimulation) and Endometrial Receptivity Analysis (ERA) are emerging/limited‑evidence strategies. Prior authorization is suggested and use should be limited to the populations described in the literature (eg, DuoStim for poor prognosis patients or when expedited retrieval is essential; ERA primarily for research or selected clinical scenarios). Consider standard approaches first and document rationale when these options are pursued.

    • DuoStim: reserve for poor prognosis patients or time‑sensitive fertility preservation; require documentation of prior standard approaches and rationale
    • ERA: considered research use in many settings; document biopsy results and personalized ET timing when performed
    Prior Authorization

    UTx (Uterine Transplant) — Documentation and Prior Authorization Recommended

    Uterine transplantation (UTx) is experimental, complex, and associated with substantial morbidity. Prior authorization is recommended before referral or scheduling. Candidates require multidisciplinary evaluation at experienced centers that meet programmatic and reporting requirements; document extensive pre‑operative testing, multidisciplinary consultations, and informed consent about risks and expected outcomes.

    • UTx is experimental — prior authorization strongly recommended
    • Document multidisciplinary consultations: gynecology, transplant surgery, psychology, immunology, anesthesiology, internal medicine, radiology
    • Document center qualifications, case volume, outcomes reporting and patient counseling
    Billing Rule

    Medication Limits and Benefit‑Check Prior to Authorization

    Medication limits and benefit verification are required prior to authorization. Many plans exclude coverage for infertility injectables or sterilization reversals; some plans require pharmacy benefit review by Specialty Pharmacy Guideline Management. Verify the member’s benefit design for drug versus medical benefit coverage, plan‑specific exclusions, quantity limits, and brand‑step requirements (eg, Follistim AQ requires trial/failure of Gonal‑F per brand‑step policy).

    • Check if injectables are covered under the pharmacy or medical benefit and whether Specialty Pharmacy review is required
    • Dose/vial limits and standard limits are specified in the Appendix (eg, per‑28 day vial/cartridge limits)
    • Brand‑step: Follistim AQ covered only after contraindication/intolerance/ineffective response to Gonal‑F
    Documentation Required

    ICSI Coverage Conditions

    ICSI is medically necessary in defined circumstances (eg, azoospermia/oligospermia, severe semen deficits, fertilization of frozen oocytes, iatrogenic infertility). If severe male factor infertility has been previously documented and then normalized after varicocelectomy, ICSI is considered not medically necessary. Document prior semen analyses and treatments.

    • ICSI indications: azoospermia, severe sperm deficits, frozen oocyte fertilization, iatrogenic infertility due to cancer therapies
    • If prior severe male‑factor resolved by varicocelectomy and semen normalizes, ICSI is not medically necessary
    Note

    Operational Note — Authorization May Be Plan‑Specific

    Some areas of this section describe prior authorization operational details or code listings only in the CPB code tables and appendices. Not every specific authorization requirement is enumerated here — always verify plan‑specific prior authorization rules during benefit check.

    • When authorization requirements are not specified in the CPB, use benefit verification tools or contact Aetna for plan‑specific rules
    • CPBs are a guide and do not replace plan contract language
    Denial Risk

    Plan Exclusions, Coding‑Based Denial Risk, and Not‑Covered Codes

    Plan exclusions and coding can trigger denials. Certain CPT/HCPCS/ICD‑10 codes are explicitly listed as not covered or limited for indications in this bulletin. Use correct diagnosis and procedure coding; avoid codes listed as not covered for CPB indications to reduce denial risk.

    • Review CPB code lists for not‑covered codes and ICD‑10 exclusions
    • Examples of HCPCS/CPT code groups and HCPCS storage/monitoring codes: S4027, S4040, S4042
    • Coding errors or use of excluded ICD‑10 codes may lead to denial
    Denial Risk

    IVM Considered Investigational — Prior Authorization/Research Setting

    In‑vitro maturation (IVM) and cryopreservation of immature oocytes are considered investigational/experimental. These procedures should only be performed in specialized centers under research protocols and will generally require prior authorization and informed‑consent documentation.

    • IVM: experimental — limit to specialized centers and research settings
    • Document patient counseling regarding lower implantation/pregnancy rates compared with standard IVF
    Documentation Required

    Contraindications May Preclude Coverage — Document FDA Label Considerations

    Contraindications and FDA boxed warnings for reproductive drugs must be checked and documented prior to prescribing. FDA‑label contraindications (eg, hypersensitivity, primary gonadal failure, tumors, pregnancy when applicable) may preclude coverage or use and should be addressed in the medical record submitted for authorization.

    • Review FDA contraindications/warnings for follitropins, menotropins, hCG preparations prior to administration
    • Document clinical rationale when dispensing agents with label warnings and monitor for OHSS and other listed risks
    Prior Authorization

    DuoStim — Restricted Use and Prior Authorization Considerations

    DuoStim should be considered primarily for poor‑prognosis patients or when time is critical. It is a later‑line or expedited option after standard stimulation cycles have been tried or when rapid fertility preservation is needed; prior authorization and clear documentation of prior treatments and rationale are recommended.

    • DuoStim: apply only to poor prognosis patients or time‑sensitive cases; freeze‑all mandatory and require documentation of prior standard approaches
    • No RCTs or cost‑effectiveness data are yet definitive — document shared decision making
    Documentation Required

    ERA — Research Use Recommended; Documentation Required

    ERA testing remains of uncertain routine benefit; many sources recommend use primarily in research or select clinical contexts. When ERA is performed, submit ERA biopsy reports and documentation of personalized embryo transfer timing and rationale with authorization requests.

    • ERA documentation elements to include: biopsy result, receptive/non‑receptive result, personalized ET timing, indication (eg, recurrent implantation failure)
    • Routine use of ERA in unselected patients is not broadly supported — consider research protocol or select indications
    Documentation Required

    CFTR Testing and Counseling — Documentation Required

    For congenital bilateral absence of the vas deferens (CBAVD) and related scenarios, CFTR genetic testing and counseling for the patient and partner should be documented when indicated. Semen fructose and other diagnostic tests and counseling should also be recorded.

    • Document CFTR testing for man with CBAVD and testing/counseling of partner
    • Record semen fructose and low volume/absent vas deferens findings and genetic counseling notes
    Denial Risk

    Experimental Status May Trigger Denial — Prior Authorization and Documentation Recommended

    Experimental procedures (eg, many add‑ons, UTx, IVM, novel genetic tests without established clinical utility) may lead to denial when billed outside approved research protocols or without prior authorization. Clearly document indication, prior treatments, and why approved alternatives are unsuitable.

    • Experimental status of UTx and other procedures often triggers denials without prior authorization and documentation
    • When pursuing experimental therapies, include evidence summary, informed consent, and justification for clinical use
    Documentation Required

    High Likelihood of COH‑IUI Futility with Specific Day‑3 Hormone Profile

    Patients with specific Day‑3 hormonal profiles (FSH 10–15 mIU/ml and E2 ≥ 40 pg/ml) have a high likelihood of COH‑IUI futility. Document Day‑3 FSH and E2 when considering COH‑IUI and consider proceeding to IVF when these markers predict poor response to COH‑IUI.

    • Day‑3 FSH 10–15 mIU/ml and E2 ≥ 40 pg/ml: specificity and PPV for no live‑birth with COH‑IUI were high in cited trials
    • Document hormonal test dates and values (FSH/E2)
    Billing Rule

    Documentation for Storage and Monitoring Services (HCPCS Coding)

    Documentation for storage and monitoring services (eg, storage of previously frozen embryos, per‑30 day embryo storage monitoring) should use appropriate HCPCS codes (eg, S4027, S4040, S4042) and include dates, consent for storage, and monitoring plan.

    • Use HCPCS codes S4027, S4040, S4042 for embryo storage/monitoring and include storage start/end dates and consent forms
    • Include monitoring documentation and inventory of cryopreserved specimens
    Documentation Required

    Ovarian Responsiveness Documentation Required

    Ovarian responsiveness must be documented prior to ovarian stimulation: obtain an unmedicated day‑3 FSH within 12 months for age ≤35 or within 6 months for age >35. In women >40, any single FSH >19 mIU/mL indicates ovarian insufficiency. In women <40, an unmedicated day‑3 FSH <19 mIU/mL demonstrates capacity to respond.

    • Unmedicated day‑3 FSH timing: ≤35 years — within prior 12 months; >35 years — within prior 6 months
    • Document FSH values and dates in authorization package
    Documentation Required

    Ovarian Cyst Aspiration — Documentation of Rationale Required

    Ovarian cyst aspiration prior to stimulation lacks conclusive benefit. If performed, document clinical rationale, cyst characteristics, and why conservative management was not chosen; be aware evidence does not support routine aspiration to improve live‑birth or cycle outcomes.

    • Document cyst size, ultrasound characteristics, rationale for aspiration, informed consent, and anesthesia/surgical notes when applicable
    Documentation Required

    Indication Documentation for Drugs and Procedures

    Indication documentation is required for infertility medications and procedures. For drug therapies, document FDA‑approved indication, prior treatments, contraindications or intolerances to alternatives, and clinical rationale for the selected agent.

    • Include prior therapy trials and response, FDA‑label indication for the drug, and any contraindications to alternatives in the medical record submitted for authorization
    Documentation Required

    ERA — Required Documentation Elements

    ERA documentation elements: include the endometrial biopsy report, ERA receptive/non‑receptive result, timing recommendations for personalized embryo transfer (pET), and clinical indication (eg, recurrent implantation failure). Submit these with authorization requests.

    • ERA report, date of biopsy, receptive vs non‑receptive classification, recommended pET timing, and indication for testing
    Documentation Required

    CFTR Testing — Documentation Required

    CFTR testing documentation: when indicated (eg, CBAVD or low semen volume with absent vas), document CFTR testing results for the patient and partner, counseling provided, and any genetic counseling referrals.

    • Record CFTR test date, method, results, partner testing status, and documented counseling/referral notes
    Documentation Required

    Testing and Counseling Documentation for Male Infertility

    Testing and counseling documentation for male infertility should include semen analysis results (use WHO reference values), semen fructose when vas absence suspected, counseling about genetic risks, and documentation of follow‑up plans.

    • Semen analysis should report WHO reference parameters (pH, concentration, morphology, volume, motility, total sperm number, vitality)
    • Document counseling and genetic testing when indicated (eg, CBAVD)
    Documentation Required

    Multidisciplinary Evaluation Documentation for Complex Interventions

    Multidisciplinary evaluation documentation is required for complex procedures (eg, UTx) — include consultations from gynecology, transplant surgery, psychology, immunology, anesthesiology, internal medicine, radiology, and any other specialty involved. Document testing, psychosocial evaluation, and informed consent.

    • Include multidisciplinary consult notes, testing results, center capabilities, and documented informed consent in authorization requests for complex interventions
    Documentation Required

    Cycle Monitoring and Medication Documentation

    Cycle monitoring and medication documentation: record serial ultrasounds, serum hormone values, medication types/doses/dates, response to stimulation, and any adverse events. Appendix specifies medically necessary counts of monitoring tests per cycle — use that guidance when documenting.

    • Document transvaginal ultrasound counts per cycle, estradiol/FSH/LH/progesterone measurements as applicable, medication name/dose/lot and administration dates
    • Follow Appendix laboratory and gonadotropin vial management limits when requesting authorization
    Documentation Required

    Semen Analysis — WHO Parameters and Repeat Testing

    Semen analysis reporting should use WHO reference values and include key parameters (pH, concentration, morphology, volume, motility, total sperm number, vitality). Repeat abnormal semen analyses on at least 2 occasions ≥2 weeks apart when defining mild or severe male‑factor infertility.

    • Repeat abnormal sperm parameters on 2 separate occasions at least 2 weeks apart to define severity
    • Severe deficits: <10 million TMS unwashed or <3 million TMS washed; severe morphology <4% (Kruger strict)
    Note

    Bibliography and References

    This section contains references and bibliographic material. Providers must consult the cited clinical literature and practice guidelines when preparing authorization requests or when considering emerging/experimental procedures.

    • Refer to CPB references and cited trials/guidelines when needed
    Note

    Provider Documentation Note and Coverage Disclaimer

    Provider documentation note: CPBs are a partial description of plan benefits and do not replace plan contracts. Providers should verify member benefits, prior authorization requirements, and plan exclusions; document all clinical findings and rationale submitted for review.

    • Clinical Policy Bulletins do not guarantee coverage — verify contract/benefit details before proceeding
    • Include complete documentation to support medical necessity determinations
    Infertility services for natural menopause in women ≥40 years are not covered because natural menopause is not considered a disease
    Premature ovarian failure allowanceWomen <40 with Day‑3 FSH > 19 mIU/mL are considered to have premature ovarian failure; ART via donor oocytes considered medically necessary until age 45
    Mild male-factor infertility definition
    Mild male‑factor infertility definitionDefined for AI: two or more semen analyses at least two weeks apart with one or more variables below the 5th percentile (per plan/NICE guidance)
    Use in AI eligibilityMeets indication for intra‑uterine or intra‑cervical insemination when present
    DocumentationRepeat semen analyses are required to establish mild male‑factor infertility
    ART cycle definition
    ART cycle definitionAn ART cycle may be IVF (fresh embryos), IVF/frozen embryo transfer (FET), GIFT, or ZIFT
    Elective single embryo transfer noteAetna may consider single fresh embryo transfer with immediate transfer of one cryopreserved embryo as part of the same IVF cycle under plan limits
    Plan variationCheck benefit plan descriptions for cycle limits and ART coverage
    Primary vs Secondary infertility
    Primary vs Secondary infertilityPrimary infertility: couple has never achieved a pregnancy; Secondary infertility: at least one prior conception
    RelevanceUsed to classify patients and guide evaluation and treatment planning
    Source guidanceASRM definitions referenced in policy background
    Ovarian responsiveness / diminished ovarian reserve
    Ovarian responsiveness / diminished reserveNormal response: ≥3 follicles and peak estrogen ≥500 mIU/ml after stimulation; diminished reserve: peak estrogen <500 mIU/ml or <3 follicles
    Assessment methodsDetermined by unmedicated Day‑3 FSH timing and thresholds plus response to gonadotropin stimulation
    Implication for coverageCoverage of ovarian stimulation therapies restricted to women who demonstrate biologic capacity to respond per these criteria
    Recurrent miscarriage defined
    Recurrent miscarriage definitionDefined as loss of 3 or more consecutive pregnancies
    Distinct from infertilityRecurrent pregnancy loss has separate evaluation and treatment considerations
    Evidence noteASRM/other committee definitions referenced in policy
    In vitro maturation (IVM) definition
    In vitro maturation (IVM) definitionMaturation in culture of immature oocytes recovered without prior exposure to LH or hCG to induce meiotic resumption; considered experimental
    RecommendationShould be limited to specialized centers and research settings until more evidence is available
    Clinical implicationNot standard of care for routine infertility treatment
    DuoStim definition
    DuoStim definitionAn IVF approach with two stimulation/aspiration cycles within the same ovarian cycle (follicular and luteal phase stimulations) to increase oocyte yield
    Primary use caseApplied mainly to poor prognosis patients or when time is critical (e.g., oncologic fertility preservation)
    Evidence statusPromising observational data but lacks extensive RCT evidence; consider restricted use pending further validation
    Eeva definition
    Eeva definitionComputer‑automated time‑lapse embryo assessment platform producing scores predicting blastocyst development to aid embryo selection
    Evidence conclusionSome studies show improved specificity for blastocyst prediction, but current evidence insufficient to support routine use for improving embryo selection
    Policy stanceEeva considered investigational for routine embryo selection
    DuoStim (duplicate definition)
    DuoStim (duplicate)Double stimulation in follicular and luteal phases within the same cycle to retrieve two cohorts of oocytes
    Clinical noteReported increases in oocyte/euploid blastocyst yield in poor‑prognosis cohorts; safety and broader efficacy require more data
    RecommendationConsider only for selected patients until further RCT evidence available
    ERA definition
    ERA definitionEndometrial Receptivity Analysis (ERA): uses endometrial biopsy RNA with NGS and a predictor to classify endometrium as receptive or non‑receptive and guide personalized embryo transfer timing
    Evidence statusMixed evidence including one RCT with per‑protocol benefits but limited ITT benefit; routine use in unselected patients not supported
    Recommended useOffer ERA selectively (e.g., prior failed ET) or in research protocols with counseling
    HL-VMB / LL-VMB microbiota definitions
    HL‑VMB / LL‑VMB definitionsHL‑VMB: dominance by specific Lactobacillus spp. or Nugent score 0–3; LL‑VMB: otherwise — HL‑VMB was negatively associated with infertility in meta‑analysis
    Evidence noteSystematic review found HL‑VMB associated with lower odds of infertility but mechanisms unclear
    Clinical implicationVaginal microbiota evaluation not established as routine management option
    CBAVD / CAVD definition
    CBAVD / CAVD definitionCongenital bilateral (or unilateral) absence of the vas deferens often associated with CFTR mutations and male infertility
    Testing recommendationTest affected man and his partner for CFTR mutations and provide counseling due to high mutation frequency and reproductive risk
    Reproductive riskIf female partner is carrier, risk to offspring may be up to 25% (heterozygous father) or higher if homozygous
    PICSI definition
    PICSI definitionPhysiological ICSI using hyaluronan‑selected sperm; a randomized trial showed no significant improvement in term live‑birth versus standard ICSI
    RecommendationWider routine use of PICSI is not recommended based on current evidence
    Study sizeLarge RCT with 2,772 couples found no significant difference in term live‑birth
    Absolute uterine factor infertility (AUFI) definition
    Absolute uterine factor infertility (AUFI)Infertility fully attributable to uterine absence (congenital or surgical) or an anatomic/functional abnormality preventing implantation or completion of pregnancy
    UTx statusUterus transplantation can restore fertility in AUFI but is experimental with substantial perioperative morbidity and high complication rates
    Program requirementsCandidates require extensive multidisciplinary evaluation and counseling; inclusion/exclusion criteria remain evolving
    Oocyte definition
    Oocyte definitionOocyte = egg
    ContextUsed in glossary and cycle descriptions throughout policy
    RelevanceDistinguishes donor oocyte, autologous oocyte and cryopreserved oocyte uses
    WHO classification of ovulatory disorders
    WHO classification of ovulatory disordersGroup I: hypothalamic pituitary failure; Group II: hypothalamic pituitary dysfunction (predominantly PCOS); Group III: ovarian failure
    Clinical applicationGuides selection of ovulation induction strategies (e.g., CC, metformin, gonadotropins)
    SourceWHO classification referenced in policy appendix
    Embryo quality (reasonable/grade B) definition
    Embryo quality (reasonable/grade B)An embryo with less than 50% fragmentation is considered reasonable quality (grade B equivalent)
    UseApplied when assessing embryo transfer decisions and cryopreservation candidacy
    SourcePolicy appendix definitions
    Poor fertilization rate definition
    Poor fertilization rate definitionIVF cycles resulting in < 50% fertilization are considered poor
    ImplicationMay trigger consideration of ICSI or laboratory/sperm evaluation interventions
    SourcePolicy appendix definitions
    Embryo Quality (ART) duplicate definition
    Embryo Quality / Fertilization Rate (duplicate definitions)Embryo reasonable quality: <50% fragmentation; Poor IVF fertilization: <50% fertilization
    Clinical relevanceDefinitions used to classify cycle outcomes and guide next‑step management
    SourcePolicy appendix
    Fertilization Rate (IVF) duplicate
    Fertilization Rate (IVF) duplicateFertilization rates <50% are considered poor in IVF cycles
    ConsequencePoor fertilization may justify ICSI or alternative strategies
    SourceAppendix definitions
    Ovarian Reserve (response to gonadotropin stimulation)
    Ovarian Reserve (response to gonadotropin stimulation)Normal: ≥3 follicles and peak estrogen >500 mIU/ml after stimulation; Diminished: peak estrogen <500 mIU/ml or <3 mature follicles
    Use in policyDefines expected response and criteria for considering alternative approaches (donor oocyte, etc.)
    SourcePolicy appendix definitions
    Severe semen quantity/quality definitions
    Severe semen quantity definitionUnwashed TMS <10 million per ejaculate or washed TMS <3 million (on two occasions ≥2 weeks apart) defines severe quantity deficit
    Severe semen quality definitionKruger strict morphology <4% normal forms defines severe quality deficit
    ICSI exceptionIf sperm normalizes after varicocelectomy, ICSI may be considered not medically necessary
    WHO semen reference values
    WHO semen reference values (key thresholds)pH ≥ 7.2; sperm concentration ≥15 million/ml; morphology ≥4% normal forms; semen volume ≥1.5 ml; total motility ≥40% (or ≥32% progressive); total sperm number ≥39 million; vitality ≥58% live
    UseReference values for reporting and interpreting semen analyses in policy
    DocumentationSevere deficits require confirmation on two occasions at least 2 weeks apart
    Endometriosis surgical staging (ASRM)
    Endometriosis surgical staging (ASRM) — overviewStages I–IV: I minimal (superficial lesions ± few filmy adhesions); II mild (some deep lesions in cul‑de‑sac); III moderate (endometriomas + more adhesions); IV severe (large endometriomas, extensive adhesions)
    Clinical relevanceStaging informs surgical and ART treatment decisions
    SourceASRM revised classification as presented in policy appendix
    Infertility definitions and committee opinions
    Referenced definitions and committee opinionsASRM Practice Committee and related committee opinions define infertility and recurrent pregnancy loss referenced in policy
    UsePolicy aligns definitions with cited guideline documents; see references for full text
    Citation notePractice Committee documents cited in references section
    Clinical Policy Bulletin
    Clinical Policy Bulletin disclaimerClinical Policy Bulletins are developed to assist in administering plan benefits and do not constitute offers of coverage or medical advice
    Provider responsibilityProviders must verify specific plan benefit documents for coverage determinations
    Effective/Review datesPolicy effective date 05/20/1999; last review 02/15/2024; next review 07/25/2024